Telix Financial Statements From 2010 to 2024

Stocks . Australia . 
Stock . Telix Pharmaceuticals
TLX Stock   25.74  0.80  3.21%   
Telix Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Telix Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Telix Pharmaceuticals financial statements helps investors assess Telix Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Telix Pharmaceuticals' valuation are summarized below:
Gross Profit
98.5 M
Profit Margin
0.0762
Market Capitalization
8.4 B
Enterprise Value Revenue
13.3722
Revenue
645.7 M
There are currently eighty-nine fundamental trend indicators for Telix Pharmaceuticals that can be evaluated and compared over time across competition. All traders should double-check Telix Pharmaceuticals' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.

Telix Pharmaceuticals Total Revenue

521.49 Million

Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 13.8 M, Other Operating Expenses of 473.6 M or Operating Income of 54.5 M, as well as many indicators such as . Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Telix Pharmaceuticals Technical models . Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Telix Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding221.8 M323.7 M184.4 M
Slightly volatile
Total Assets418.2 M398.3 M126.5 M
Slightly volatile
Total Current Liabilities165.3 M157.4 M33 M
Slightly volatile
Total Stockholder Equity156.4 M148.9 M62.9 M
Slightly volatile
Property Plant And Equipment Net32 M30.5 M6.7 M
Slightly volatile
Accounts Payable34.5 M32.8 M7.6 M
Slightly volatile
Cash63.5 M123.2 M54.5 M
Slightly volatile
Non Current Assets Total182.1 M173.5 M45.2 M
Slightly volatile
Cash And Short Term Investments63.5 M123.2 M54.5 M
Slightly volatile
Net Receivables68 M64.8 M15.5 M
Slightly volatile
Common Stock Total Equity201.7 M192.1 M99.1 M
Slightly volatile
Liabilities And Stockholders Equity418.2 M398.3 M126.5 M
Slightly volatile
Non Current Liabilities Total48.8 M92 M27.1 M
Slightly volatile
Total Liabilities261.9 M249.4 M63.3 M
Slightly volatile
Property Plant And Equipment Gross38.1 M36.3 M7.9 M
Slightly volatile
Total Current Assets236.1 M224.8 M81.3 M
Slightly volatile
Common Stock468.6 M446.3 M147.7 M
Slightly volatile
Short and Long Term Debt Total18.3 M17.4 M3.8 M
Slightly volatile
Other Current Liabilities105.5 M100.5 M20.1 M
Slightly volatile
Other Liabilities96.6 M92 M28.8 M
Slightly volatile
Other Assets4.8 M4.6 M1 M
Slightly volatile
Good Will4.1 M4.8 M2.2 M
Slightly volatile
Inventory18.2 M17.3 M3.4 M
Slightly volatile
Other Current Assets20.5 M19.5 M3.6 M
Slightly volatile
Net Invested Capital166 M158.1 M67.4 M
Slightly volatile
Short and Long Term Debt911 K867.6 K492.7 K
Slightly volatile
Net Working Capital56.9 M67.4 M50.4 M
Pretty Stable
Short Term Debt874.9 K1.6 M590.7 K
Slightly volatile
Intangible Assets56.3 M104.8 M28.2 M
Slightly volatile
Property Plant Equipment22.7 M21.7 M5.1 M
Slightly volatile
Current Deferred Revenue6.4 M11 M4.5 M
Slightly volatile
Capital Stock246.2 M446.3 M144.4 M
Slightly volatile
Non Current Liabilities Other19 M12.2 M16.4 M
Slightly volatile
Capital Lease Obligations4.7 M8.3 M2.5 M
Slightly volatile
Long Term Investments9.8 M11 M12 M
Slightly volatile

Telix Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses473.6 M451 M92 M
Slightly volatile
Depreciation And Amortization7.1 M6.7 M2.3 M
Slightly volatile
Selling General Administrative82.9 M79 M20 M
Slightly volatile
Research Development135.3 M128.8 M28.2 M
Slightly volatile
Interest Income626.2 K1 M425.2 K
Slightly volatile
Selling And Marketing Expenses57.6 M54.9 M9.2 M
Slightly volatile
Reconciled Depreciation4.2 M6.7 M2 M
Slightly volatile

Telix Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation7.3 M6.9 M2.3 M
Slightly volatile
Capital Expenditures11.3 M10.8 M2.6 M
Slightly volatile
Stock Based Compensation9.2 M8.8 M2.2 M
Slightly volatile
Dividends Paid203.4 M193.7 M85 M
Slightly volatile
End Period Cash Flow72.1 M123.2 M58.1 M
Slightly volatile
Issuance Of Capital Stock6.3 M6.7 M45.7 M
Very volatile

Telix Fundamental Market Drivers

Forward Price Earnings21.0084
Cash And Short Term Investments123.2 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Telix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Telix Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Telix Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11 M6.4 M
Total Revenue496.7 M521.5 M
Cost Of Revenue188.2 M197.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY